Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

8 August 2022

BioNTech Announces Second Quarter Financial Results and Corporate Update

5 August 2022

BioNTech and Genmab Expand Global Strategic Collaboration to Develop and Commer..

27 July 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-..

Press releases (more)

Upcoming Events

September 12 - September 14, 2022

Morgan Stanley Annual Global Healthcare Conference

September 14 - September 16, 2022

BofA Global Healthcare Conference

September 19 - September 21, 2022

Berenberg & Goldman Sachs German Corporate Conference

Upcoming events (more)

Stock Quote

Aug 17, 2022 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.